Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens

被引：2
|
作者：
Sebert, Marie [1 ,2 ,3 ,4 ]
Freiman, Lucie [3 ]
Chaffaut, Cendrine [5 ]
Guerci, Agnes [4 ,6 ]
Peterlin, Pierre [4 ,7 ]
Thepot, Sylvain [4 ,8 ]
Beyne-Rauzy, Odile [4 ,9 ]
Park, Sophie [4 ,10 ]
Cluzeau, Thomas [4 ,11 ]
Chermat, Fatiha [4 ]
Fenaux, Pierre [1 ,2 ,3 ,4 ]
Preudhomme, Claude [12 ]
Clappier, Emmanuelle [1 ,2 ,13 ]
Chevret, Sylvie [5 ]
Ades, Lionel [1 ,2 ,3 ,4 ]
Duployez, Nicolas [1 ,2 ,12 ,13 ]
Duchmann, Matthieu [1 ,2 ,13 ]
机构：
[1] Univ Paris, Unite 944 7212, GenCellDi, INSERM, Paris, France
[2] CNRS, Paris, France
[3] St Louis Hosp, AP HP, Hematol Dept, Paris, France
[4] Grp Francophone Myelodysplasies, Paris, France
[5] St Louis Hosp, AP HP, Biostat Dept, Paris, France
[6] CHU Brabois Vandoeuvre, Hematol Dept, Nancy, France
[7] Nantes Univ Hosp, Hematol Dept, Nantes, France
[8] Angers Univ Hosp, Hematol Dept, Angers, France
[9] CHU Toulouse, Inst Univ Canc Toulouse Oncopole, Hematol Dept, Toulouse, France
[10] Grenoble Univ Hosp, Hematol Dept, Grenoble, France
[11] Nice Univ Hosp, Hematol Dept, Nice, France
[12] Univ Lille, CHU Lille, Hematol Lab, INSERM,Unite 1277,Canc Heterogene Plast & Resistan, Lille, France
[13] St Louis Hosp, AP HP, Hematol Lab, Paris, France
来源：
LEUKEMIA | 2024年 / 38卷 / 04期
关键词：
D O I：
10.1038/s41375-024-02180-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：918 / 922
页数：5
相关论文
共 11 条
  • [1] Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens
    Marie Sébert
    Lucie Freiman
    Cendrine Chaffaut
    Agnès Guerci
    Pierre Peterlin
    Sylvain Thépot
    Odile Beyne-Rauzy
    Sophie Park
    Thomas Cluzeau
    Fatiha Chermat
    Pierre Fenaux
    Claude Preudhomme
    Emmanuelle Clappier
    Sylvie Chevret
    Lionel Adès
    Nicolas Duployez
    Matthieu Duchmann
    Leukemia, 2024, 38 : 918 - 922
  • [2] GERMLINE DDX41 MUTATIONS : A SIGNIFICANT ENTITY WITHIN ADULT MDS/AML PATIENTS
    Sebert, M.
    LEUKEMIA RESEARCH, 2023, 128
  • [3] Germline DDX41 mutations define a significant entity within adult MDS/AML patients
    Sebert, Marie
    Passet, Marie
    Raimbault, Anna
    Rahme, Ramy
    Raffoux, Emmanuel
    de Fontbrune, Flore Sicre
    Cerrano, Marco
    Quentin, Samuel
    Vasquez, Nadia
    Da Costa, Melanie
    Boissel, Nicolas
    Dombret, Herve
    de Latour, Regis Peffault
    Socie, Gerard
    Itzykson, Raphael
    Fenaux, Pierre
    Soulier, Jean
    Ades, Lionel
    Clappier, Emmanuelle
    BLOOD, 2019, 134 (17) : 1441 - 1444
  • [4] Healthcare utilization in patients with higher-risk MDS/low-blast count AML treated with azacitidine in the 'real-world'
    Mozessohn, Lee
    Cheung, Matthew C.
    Mittmann, Nicole
    Earle, Craig C.
    Liu, Ning
    Buckstein, Rena
    LEUKEMIA & LYMPHOMA, 2020, 61 (06) : 1445 - 1454
  • [5] OUTCOME OF AZACITIDINE TREATMENT AND INCIDENCE OF FEBRILE EVENTS IN "REAL WORLD" PATIENTS WITH MDS OR LOW-BLAST COUNT AML
    Voso, M. T.
    Niscola, P.
    Piciocchi, A.
    Fianchi, L.
    Maurillo, L.
    Musto, P.
    Pagano, L.
    Mansueto, G.
    Criscuolo, M.
    Aloe-Spiriti, M. A.
    Buccisano, F.
    Venditti, A.
    Tendas, A.
    Piccioni, A. L.
    Zini, G.
    Latagliata, R.
    Filardi, N.
    Fragasso, R.
    Fenu, S.
    Breccia, M.
    LEUKEMIA RESEARCH, 2015, 39 : S99 - S99
  • [6] Favorable Outcomes of DDX41-Mutated MDS and Low Blast Count AML Treated with Azacitidine with or without Lenalidomide (ALLG MDS4 Trial)
    Tiong, Ing S.
    Stevenson, William S.
    Wall, Meaghan
    Yap, Yan Zhuang
    Seymour, John F.
    Kenealy, Melita
    Blombery, Piers
    BLOOD, 2022, 140 : 4090 - 4091
  • [7] Prognostic Significance of DDX41 Germline Mutations in Intensively Treated AML Patients: An ALFA-Filo Study
    Duployez, Nicolas
    Duchmann, Matthieu
    Largeaud, Laetitia
    Lambert, Juliette
    Bidet, Audrey
    Clappier, Emmanuelle
    Thomas, Xavier
    de Botton, Stephane
    Gardin, Claude
    Recher, Christian
    Pigneux, Arnaud
    Itzykson, Raphael
    Preudhomme, Claude
    Dombret, Herve
    Delabesse, Eric
    Sebert, Marie
    BLOOD, 2021, 138
  • [8] Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study
    Duployez, Nicolas
    Largeaud, Laetitia
    Duchmann, Matthieu
    Kim, Rathana
    Rieunier, Julie
    Lambert, Juliette
    Bidet, Audrey
    Larcher, Lise
    Lemoine, Jean
    Delhommeau, Francois
    Hirsch, Pierre
    Fenwarth, Laurene
    Kosmider, Olivier
    Decroocq, Justine
    Bouvier, Anne
    Le Bris, Yannick
    Ochmann, Marlene
    Santagostino, Alberto
    Ades, Lionel
    Fenaux, Pierre
    Thomas, Xavier
    Micol, Jean-Baptiste
    Gardin, Claude
    Itzykson, Raphael
    Soulier, Jean
    Clappier, Emmanuelle
    Recher, Christian
    Preudhomme, Claude
    Pigneux, Arnaud
    Dombret, Herve
    Delabesse, Eric
    Sebert, Marie
    BLOOD, 2022, 140 (07) : 756 - 768
  • [9] High Healthcare Utilization and Costs in Patients with Higher-Risk MDS/Low Blast Count AML Treated with Azacitidine in Ontario, Canada
    Mozessohn, Lee
    Cheung, Matthew
    Mittmann, Nicole
    Earle, Craig C.
    Liu, Ning
    Buckstein, Rena
    BLOOD, 2018, 132
  • [10] Feasibililty of Azacitidine As Bridge to Allogeneic Stem Cell Transplantation in Patients with Higher-Risk MDS or Low-Blast Count AML: Results of the BMT-AZA Multicenter Prospective Study
    Voso, Maria Teresa
    Leone, Giuseppe
    Piciocchi, Alfonso
    Fianchi, Luana
    Di Bartolomeo, Paolo
    Candoni, Anna
    Criscuolo, Marianna
    Masciulli, Arianna
    Cerqui, Elisa
    Molteni, Alfredo
    Finelli, Carlo
    Parma, Matteo
    Rivellini, Flavia
    Cascavilla, Nicola
    Spina, Francesco
    Cortelezzi, Agostino
    Salvi, Flavia
    Montanari, Mauro
    Alessandrino, Emilio Paolo
    Rambaldi, Alessandro
    Sica, Simona
    BLOOD, 2015, 126 (23)
12